Jeffrey Poulton Sells 2,206 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Jeffrey Poulton sold 2,206 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total value of $722,795.90. Following the transaction, the executive vice president directly owned 64,273 shares of the company’s stock, valued at $21,059,048.45. The trade was a 3.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY opened at $320.51 on Friday. The business’s 50 day moving average price is $353.84 and its 200-day moving average price is $415.74. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. The firm has a market capitalization of $42.51 billion, a PE ratio of 187.43 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). The business had revenue of $1.10 billion for the quarter, compared to analysts’ expectations of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.Alnylam Pharmaceuticals’s quarterly revenue was up 84.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.65) EPS. As a group, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Brighton Jones LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $243,000. Geneos Wealth Management Inc. increased its holdings in Alnylam Pharmaceuticals by 372.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 175 shares during the last quarter. AlphaQuest LLC purchased a new stake in Alnylam Pharmaceuticals in the second quarter valued at approximately $43,000. Bessemer Group Inc. raised its position in Alnylam Pharmaceuticals by 77.8% in the second quarter. Bessemer Group Inc. now owns 192 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 84 shares during the period. Finally, Hantz Financial Services Inc. acquired a new position in Alnylam Pharmaceuticals during the second quarter worth $124,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analysts Set New Price Targets

ALNY has been the subject of several recent research reports. Morgan Stanley cut their price target on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a report on Friday, January 30th. Wells Fargo & Company dropped their target price on Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a report on Tuesday, January 20th. Raymond James Financial reiterated an “outperform” rating and set a $472.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, January 12th. Bank of America reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. Finally, Royal Bank Of Canada cut their price objective on shares of Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a research report on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $477.96.

Alnylam Pharmaceuticals News Roundup

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Signed a research collaboration with Tenaya Therapeutics to discover and validate genetic targets for cardiovascular disease; the deal includes upfront cash and research funding plus up to $1.13 billion in milestone payments, expanding Alnylam’s RNAi pipeline into a large disease area. Read More.
• Positive Sentiment: Coverage notes a reimbursement win and reported trial progress for Alnylam’s programs — improving near?term commercial visibility for approved RNAi medicines and supporting revenue upside against current valuation. Read More.
• Positive Sentiment: Industry backdrop remains supportive: market reports project strong growth for orphan drugs, which underpins long?term demand for Alnylam’s rare?disease franchises. Read More.
• Neutral Sentiment: Short?interest figures in recent reports show zero shares and a 0.0 days?to?cover — this appears to be a reporting glitch and is unlikely to represent a real change in short positioning.
• Neutral Sentiment: Analyst coverage remains mixed to favorable with a consensus “Moderate Buy” and a wide range of price targets; useful context for longer?term expectations but not an immediate driver.
• Negative Sentiment: Significant clustered insider selling: CEO Yvonne Greenstreet reported selling ~6,799 shares (~$2.23M) and multiple EVPs sold 1.6k–2.2k shares each across March 2–3. These concurrent executive sales (disclosed in SEC filings and insider summaries) can create short?term negative sentiment and add selling pressure despite insiders retaining large holdings. Read More. Read More.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.